The recombinant plasmid pMD18-T-chVEGF and Pichia shuttle vector pPICZα-A were digested with Eco-RI and XbaI, respectively. Two kinds of DNA fragments collected from the agarose gel were conjugated with T4 DNA ligase. The recombinant vector was transformed
INTRODUCTION
Osteogenesis and angiogenesis are closely associated processes that share some essential mediators (Gerber and Ferrara, 2000; Provot and Schipani, 2005) , such as vascular endothelial growth factor (VEGF). Vascular endothelial growth factor, a cytokine that was initially thought to be endothelial specific, increases vascular permeability and angiogenesis by stimulating the proliferation, differentiation, survival, sprouting, migration, and tube formation of endothelial cells (Yancopoulos et al., 2000; Ferrara and Gerber, 2001; Tammela et al., 2005) . Today, it is well known that VEGF, which is produced by endothelial cells, fibroblasts, smooth-muscle cells, hypertrophic chondrocytes, and osteoblasts, acts as a critical modulator of endochondral and membranous ossification and that it has multiple biological functions, not only in bone angiogenesis but also in various other aspects of bone development and growth, including chondrocyte differentiation, osteoblast differentiation, osteoclast recruitment, and extracellular matrix (ECM) remodeling (Carlevaro et al., 2000; Deckers et al., 2000; Engsig et al., 2000; Nakagawa et al., 2000; Mayr-Wohlfart, 2002; Pufe et al., 2004; Zelzer and Olsen, 2005; Yao et al., 2006; Yang et al., 2008) . In mice, inhibition of VEGF activity by treatment with soluble VEGF receptor decreases angiogenesis as well as trabecular bone formation and repair, and VEGF-deletion-induced absence of vascular invasion delays endochondral ossification and expands the hypertrophic zone of growth plate cartilage (Gerber et College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, P. R. China ABSTRACT Vascular endothelial growth factor (VEGF) is an essential mediator of angiogenesis and endochondral ossification. To explore the role of VEGF in avian diseases such as tibial dyschondroplasia (TD), a typical disorder of endochondral ossification, we expressed and identified recombinant chicken VEGF (ch-VEGF) protein in Pichia pastoris and evaluated its effects on thiram-induced TD in broiler chickens. The SDS-PAGE showed that 2 recombinant proteins, with molecular weights of ~46 and ~70 kDa, were obtained. Western blot analysis indicated that the 2 proteins were recognized by rabbit anti-chicken and goat anti-human VEGF polyclonal antibodies. Moreover, the mixture of the proteins significantly stimulated angiogenesis in the chick chorioallantoic membrane. In 21-d-old broilers that had been fed a thiram-enriched diet (100 mg/kg of thiram for 2 d at 8 d old) to induce TD, intramuscular injection of the chVEGF proteins (at a dosage of 10 or 30 μg/kg) significantly reduced the severity of TD but had no effect on TD incidence or BW; decreased serum Ca and P concentrations and tartrate-resistant acid phosphatase activity and elevated serum alkaline phosphatase activity; enhanced the total antioxidant capacity, superoxide dismutase, and glutathione peroxidase activities in the liver and kidney; upregulated the expression of type X collagen, matrix metalloproteinase (MMP)-13, and Runx2; and downregulated the Bcl-2 expression in the growth plates. In thiram-treated broilers at 15 d old, the chVEGF proteins upregulated the expression of MMP-13 and Runx2, and had different effects on type X collagen and Bcl-2 expression at different dosages. Our results indicate that exogenous chVEGF proteins promoted the recovery of TD-affected growth plates by improving the antioxidant capacity in the liver and kidney and by regulating differential expression of genes relating to endochondral ossification at different stages of TD development; VEGF deficiency in the growth plates was involved in the pathogenesis of TD. al., 1999; Maes et al., 2002 Maes et al., , 2004 . Some reports have suggested that the abnormalities of vascular invasion and angiogenesis associated with VEGF may be involved in the pathological mechanisms of bone diseases such as rickets, osteoarthritis, osteoporosis, and tibial dyschondroplasia (TD; Hunter et al., 1991; Praul et al., 2000; Enomoto et al., 2003; Tanaka et al., 2005; Corrado et al., 2013) . However, the exact role of VEGF in the development of and recovery from these diseases is still unclear, especially with regard to avian bone abnormalities. Lack of exogenous active VEGF proteins has restricted further study of their roles. Tibial dyschondroplasia, a cartilage disorder that is prevalent in many avian species, is characterized by the accumulation of prehypertrophic chondrocytes that form an avascular, nonmineralized lesion in the proximal tibiotarsal bone; the disease causes lameness, bone breakage, and infection and results in enormous economic losses and is harmful to animal welfare (Leach and Nesheim, 1965; Praul et al., 2000; Farquharson, 2002) . The mechanism underlying TD development is unknown, although several theories have been advanced to explain its etiology (Farquharson and Jefferies, 2000; Leach and Monsonego-Ornan, 2007) . The destruction of growth plate vascularization may be the most important mechanism of TD development, as indicated by the fact that a distinctive characteristic of TD is disturbed vascular invasion in growth plates; all causes of TD may be linked by this mechanism (Orth and Cook, 1994) . To explore the roles of VEGF in avian diseases, especially in TD, we cloned chicken VEGF (chVEGF) gene from chicken tibia growth plates, and expressed the recombinant chVEGF protein in Pichia pastoris, determined its bioactivity, and investigated its effect on thiram-induced TD in broiler chickens.
MATERIALS AND METHODS

Experimental Materials
Escherichia coli DH5α strain, Pichia strain X-33, and shuttle vector pPICZα-A were gifts from a key open laboratory of animal disease diagnosis and immunity of the Ministry of Agriculture (Nanjing, China). The pMD18-T vector, restriction endonucleases, molecular weight markers for DNA and protein, T4 DNA ligase, TRIzol reagent, reverse transcription (RT)-PCR kits, and SYBR Premix Ex Taq kits were obtained from Takara Biotech Co. (Dalian, China). Goat anti-human VEGF (VEGF-A) polyclonal antibody was purchased from Pepro Tech EC (London, UK). Test kits for calcium, phosphate, alkaline phosphatase (ALP), tartrateresistant acid phosphatase (TRAP), total antioxidant capacity (T-AOC), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Thiram and zeocin were obtained from Sigma-Aldrich (Shanghai) Trading Co. (Shanghai, China). Other reagents, such as TIANgel Mini Purification kits, TIANprep Mini Plasmid kits, BCA kits, and Prolight HRP Chemiluminescence Detection Reagent, were bought from Tiangen Biotech Co. (Beijing, China) unless otherwise stated. All chemicals and reagents were of the highest analytical grade.
RNA Extraction, Reverse Transcription, and PCR
Total RNA was extracted from tibia growth plates of 10-d-old chicks with TRIzol reagent according to the manufacturer's protocol, and the RNA was subjected to gel electrophoresis (2% agarose) to determine its integrity. After DNase I treatment to eliminate possible genomic DNA and determination of the concentration of total RNA with an Eppendorf BioPhotometer Plus (Hamburg, Germany), RNA samples were reverse transcribed with a RT-PCR kit to generate cDNA. On the basis of the chicken VEGF gene sequence in GenBank (AY168004), a pair of specific primers (P1 and P2) were designed to clone the VEGF gene from cDNA. Meanwhile, another pair of primers (P3 and P4) containing EcoRI and XbaI restriction sites (GAATTC and TCTA-GA, respectively) were designed to subclone the objective DNA fragment. The sequences of the primers were as follows: P1, 5 ′-GGAACTTTCTGCTCACTTGG-3 ′; P2, 5 ′-GCCCGTCTCGGTTTTT-CACA-3 ′; P3, 5 ′-GTGAATTCATGAACTTTCTGCTCACTTG-GAT-3; P4, 5 ′-GGCCTCTAGATCACCGTCTCG-GTTTTTCAC-3 ′. The PCR amplification was conducted with the following protocol: initial denaturation at 94°C for 5 min; 30 cycles of denaturation at 94°C for 1 min, annealing at 56°C for 45 s, and extension at 72°C for 1 min; and extension for 10 min at 72°C. The amplified products were analyzed by electrophoresis on 2% agarose gels. The objective DNA fragments (VEGF, 579 bp) were collected from the gels with a TIANgel Midi Purification Kit and then cloned into the pMD18-T vector. The recombinant vector was transformed into E. coli DH5α. After culturing at 37°C overnight, the recombinant plasmids were extracted with a TIANprep Mini Plasmid Kit. The positive clones that had been identified by double restriction digestion and PCR were sequenced by Invitrogen Biotech Co. (Shanghai, China). As described above, the subcloned DNA fragments with primers P3 and P4 were ligated into pMD18-T vector, and the recombinant vectors were transformed into E. coli DH5α. The plasmids were extracted, and the positive clones were identified and sequenced.
into E. coli DH5α, and then the recombinant plasmid was extracted, identified, and sequenced by the methods described above. The constructed recombinant plasmid pPICZα-A-chVEGF was transformed into P. pastoris host strain X-33 by electroporation, and recombinant transformants were selected in yeast extract peptone dextrose medium [1% yeast extract (wt/vol), 2% peptone (wt/vol), 2% glucose (wt/vol), 18.22% sorbitol (wt/vol), 2% agar (wt/vol)] containing various concentrations of zeocin. After integration of the target gene with yeast genome DNA was confirmed by PCR amplification with a pair of specific primers designed on the basis of the alcohol oxidase sequence in pPICZα-A (P5 and P6), the positive transformants with a high copy number of the target gene were cultured in buffered glycerol-complex medium [1% yeast extract (wt/vol), 2% peptone (wt/vol), 100 mM potassium phosphate buffer, pH 6.0, 1.34% yeast nitrogen base (wt/vol), 4 × 10 −5 % biotin (wt/vol), 1% glycerol (vol/vol)] overnight at 30°C in a shaking incubator (300 rpm) until the OD 600 value of the bacteria liquid reached 2 to 6. After the culture liquid was centrifuged at 15,000 × g for 5 min at 4°C, the bacteria sediment was collected and resuspended in buffered methanol-complex medium [1% yeast extract (wt/vol), 2% peptone (wt/vol), 100 mM potassium phosphate buffer, pH 6.0, 1.34% yeast nitrogen base (wt/vol), 4 × 10 −5 % biotin (wt/vol), and 0.5% methanol (vol/vol)] until the OD 600 value of the bacteria liquid was approximately 1. Expression of the target protein was induced by adding enough methanol to buffered methanol-complex medium every 24 h to keep the final concentration at 0.5% (vol/vol) . After incubation at 30°C in the shaking incubator (300 rpm) for 72 h, the bacteria liquid was centrifuged, and the supernatant was collected. The primer sequences were as follows: P5, 5 ′-GACTGGTTCCAATT-GACAAG-3 ′; P6, 5 ′-GCAAATGGC AT TCTGACATCC-3 ′.
SDS-PAGE and Western Blot Analysis
After boiling for 5 min in an equal amount of 2× SDS-PAGE sample buffer [125 mM Tris-HCl, pH 6.8; 2% SDS (wt/vol); 0.1% bromophenol blue (wt/vol); 10% glycerol (vol/vol); 1% 2-mercaptoethanol (vol/ vol)], 2 samples of the supernatant were subjected to SDS-PAGE on 10% polyacrylamide gel. One sample was stained with Coomassie Brilliant Blue, and another was transferred onto nitrocellulose membranes and identified by Western blot analysis using a tank blotting system (Bio-Rad, Hercules, CA) with rabbit antichicken (1:2,000) or goat anti-human VEGF polyclonal antibody (1:500) as the first antibody (the former was prepared with chVEGF protein obtained from a prokaryotic expression system in our laboratory) followed by goat anti-rabbit IgG (1:5,000) labeled with horseradish peroxidase as the second antibody. Finally, the antigen-antibody complex was detected by means of Pro-light HRP Chemiluminescence Detection Reagent (Tiangen Biotech Co., Beijing, China).
Chick Chorioallantoic Membrane Assay
A chick chorioallantoic membrane (CAM) assay was performed to determine the activity of the recombinant proteins (Barnhill and Ryan, 1983; Kirchner et al., 1996) . Filter membranes (0.45 μm) of mixed cellulose ester were cut into discs (~5 mm diameter) by means of a perforator, and the discs were sterilized and used to carry the recombinant proteins. The recombinant proteins were purified by dialysis against 50 mM Tris-HCl and phosphate buffered saline (pH 7.6) for 48 h at 4°C, concentration with PET 6000, and membrane filtration (0.22 μm aperture). The protein concentration was determined with a BCA protein assay kit. Hatching eggs of Arbor Acres broiler chickens were incubated at 37.8°C and 70 to 80% humidity. On d 7 of development, the air chamber was opened and a window (3 cm 2 ) was cut from the eggshell. The inner shell membrane was removed to expose the CAM. After discs containing 20 ng of the recombinant proteins or 0.9% sodium chloride solution were placed on the CAM, the windows were sealed with cellotape, and the eggs were returned to the incubator. After incubating at 37.8°C for 72 h, the CAM was cut, fixed with a mixture of methanal and acetone, examined under a stereomicroscope, and photographed with a Canon digital camera (Tokyo, Japan).
In Vivo Experiment in Broiler Chickens
Eight-day-old Arbor Acres broilers (n = 320) were bought from Pukou Hatchery (Nanjing, China) and were randomly divided into 8 groups (groups A-H, 40 birds per group). Groups A and E were the basal diet control group and the thiram diet control group, respectively. Starting at 8 d old, groups E, F, G, and H were fed a diet containing 100 mg/kg of thiram for 2 d to induce TD, and then all the birds in all 8 groups were fed a normal commercial diet (basal diet) purchased from Rongchang Feed Co. (Nanjing, China). At 9, 13, and 17 d of age, recombinant chVEGF proteins were injected into the leg muscles of the birds in the 6 test groups (B-D and F-H) 3 times at a dosage of 10 μg/kg (groups B and F), 30 μg/kg (groups C and G), or 50 μg/kg (groups D and H), to produce a local effect on the proximal tibia. Growth plates from ten 15-d-old birds in each group were collected for RNA extraction and quantitative analysis of gene expression. At 21 d old, all birds were weighed and then killed by cervical dislocation. Samples of blood, tibia growth plate, liver, and kidney were collected. The right proximal tibiotarsi of all birds were dissected in longitudinal section for TD evaluation. The incidences and indexes of the birds were determined according to a previously described procedure (Rath et al., 2004) . Serum Ca, P, and ALP were determined with a biochemical autoanalyzer (Selectra-E-plus, Vital Scientific, Dieren, the Netherlands). Total antioxidant capacity, SOD, and GSH-Px activities in the liver and kidney as well as serum TRAP activity were determined with commercial reagent kits accord-ing to the manufacturer's recommended protocols. All bird and experimental procedures were approved by the Animal Ethics Committee of Nanjing Agricultural University, China.
Expression levels of the genes for Bcl-2, collagen X, matrix metalloproteinase (MMP)-13, and Runx2 in the growth plate cartilage relative to β-actin gene as an internal standard, were determined with a SYBR Premix Ex Taq Kit in an ABI-PRISM 7300 Real-Time PCR System (New York, NY) according to the manufacturers' specifications. Total RNA extraction and cDNA synthesis were performed as described above. Five pairs of specific primers were designed using Primes Premier 5.0 software according to the coding sequences of the respective chicken genes in the National Center for Biotechnology Information database, and were synthesized by Invitrogen Biotech Co. (Shanghai, China). The primer sequences of the target genes for real-time quantitative RT-PCR analysis are shown in Table 1 . The 2 −ΔΔCt method was used to analyze the real-time RT-PCR data (Livak and Schmittgen, 2001 ). Controls without DNA templates (NTC) were set. All samples were included in the same RT-PCR run, and each sample was repeated at least 3 times.
Statistics
Statistical analysis was performed with SPSS 16.0 for Windows (SPSS Inc., Chicago, IL). Values of mRNA abundance are expressed as the fold-change relative to the basal control group. Data are presented as means ± SEM. The differences were tested by ANOVA for independent samples. Differences were considered significant at P < 0.05.
RESULTS
Cloning of the chVEGF Gene
The DNA fragments of ~579 bp were obtained from total RNA of the growth plate cartilage by RT-PCR amplification (Figure 1 ). The sequencing result confirmed that the cloned gene was consistent with the corresponding chicken VEGF sequence in GenBank (National Center for Biotechnology Information).
Identification of Recombinant Expression Plasmid and Positive Transformant
After the constructed expression plasmid pPICZα-A-chVEGF was digested by EcoRI and XbaI, 2 DNA fragments of ~3.6 kb and ~579 bp were detected in the agarose gel, and a DNA fragment of ~579 bp was obtained from the recombinant plasmid by PCR amplification with primers 3 and 4 (Figure 2) . Sequencing results showed that the insertion direction of the exogenous gene and the reading frame were correct. Positive recombinants of transformed yeast with the target gene were confirmed to have 2 fragments (~1,100 and ~579 bp) by PCR amplification with the 5 ′ and 3 ′ alcohol oxidase primers (P5 and P6) designed on the basis of the alcohol oxidase sequence in the vector pPICZα-A (Figure 3 ).
Identification of chVEGF Protein by SDS-PAGE and Western Blot
Two proteins (~46 and ~70 kDa) were expressed at higher levels in P. pastoris after the positive transformants with a high copy number of the target gene were induced for 72 h by the addition of methanol ( Figure  4 ). Western blot analysis showed that the recombinant proteins were recognized by goat anti-human VEGF polyclonal antibody ( Figure 5 ) and rabbit anti-chicken VEGF polyclonal antibody ( Figure 6 ).
Bioactivity of Recombinant chVEGF Proteins
The recombinant chVEGF proteins that were secreted from P. pastoris clearly promoted angiogenesis on the CAM of 9-d-old chick embryos. Compared with the controls treated with normal saline, the embryos treated with chVEGF (20 ng) showed a higher density and number of blood vessels around the discs on the 
Effects of Recombinant chVEGF Proteins on BW, TD Incidence, TD Index, and Blood Chemistry
The effects of recombinant chVEGF proteins on BW, TD incidence, and TD index (Table 2 ) and blood chemistry (Table 3) in 21-d-old broilers were evaluated. The severity of thiram-induced TD was significantly lower (P < 0.05) in the birds injected with the recombinant proteins than in the controls, but the proteins had no distinct effect on BW or TD incidence either in the thiram-treated birds or the birds fed the basal diet. Moreover, the basal diet-fed birds injected with the recombinant proteins showed significantly higher serum Ca and P concentrations and ALP and TRAP activities (P < 0.05) than the corresponding control birds, whereas the thiram-treated birds injected with the proteins showed lower serum Ca and P concentrations and TRAP activity and higher serum ALP activity compared with the corresponding controls.
Effects of Recombinant chVEGF Proteins on Antioxidant Capacity in the Liver and Kidney
The effects of the recombinant proteins on antioxidant capacity in the liver and kidney are shown in Tables  4 and 5 . Compared with the basal diet control birds, the thiram-treated birds showed significantly lower T-AOC, SOD, and GSH-Px activities in the liver and kidney (P < 0.05). In both diet groups, birds treated with the recombinant proteins at a dosage of 10 or 30 μg/kg showed significantly higher T-AOC, SOD, and GSH-Px activities in the liver and kidney than birds in the corresponding control groups (groups A and E, respectively; P < 0.05). However, the thiram-treated birds injected with the high dosage of chVEGF (50 μg/ kg) showed lower T-AOC, SOD, and GSH-Px activities in the liver and kidney compared with the activities in the corresponding controls.
Expression of Genes Related to Vascularization and TD
The effects of the recombinant proteins on the expression of genes encoding Bcl-2, type X collagen, MMP-13, and Runx2 in the growth plates at 15 and 21 d of age are shown in Figures 8 and 9 , respectively. Thiram significantly upregulated the expression of Bcl-2 and collagen X mRNA and downregulated the expression of MMP-13 and Runx2 in 15-d-old birds. In the 21-d-old birds, thiram did not significantly affect the expression of MMP-13, but the expression levels of Bcl-2, collagen X, and Runx2 mRNA were significantly downregulated in the thiram control group compared with expression in the basal diet control group. In the thiram-treated birds at 15 d old, injection with the recombinant proteins at all dosages significantly upregulated the expression of MMP-13 and Runx2 mRNA, but the expression of Bcl-2 and type X collagen mRNA was upregulated only by the 10 μg/kg dosage at 15 d old. However, in the 21-d-old thiram-treated birds, treatment with the recombinant proteins significantly upregulated the expression of the genes encoding collagen X, MMP-13, and Runx2 but downregulated expression of the Bcl-2 gene in the growth plates in a dose-dependent manner.
DISCUSSION
Angiogenesis is a crucial part of endochondral and membranous ossification. The final event in endochondral ossification is the replacement of an avascular cartilage template by highly vascularized bone tissue (Dai and Rabie, 2007; Mackie et al., 2008) . In this process, hypertrophic chondrocytes produce a calcified cartilaginous ECM and angiogenic stimulators, thus providing a target for capillary invasion and angiogenesis (Vu and Werb, 1998; Carlevaro et al., 2000; Bluteau et al., 2007). This process is accompanied by apoptosis of terminally differentiated chondrocytes, resorption of cartilage ECM by invading osteoclasts and chondroclasts, and deposition of mineralized matrix by osteoblasts (Erlebacher et al., 1995; Dai and Rabie, 2007) . Functional defects of bone cells, such as the absence of osteoblast differentiation, impaired chondrocyte hypertrophy, disturbed chondrocyte differentiation, and defective matrix degradation, have been associated with impaired angiogenesis (Komori et al., 1997; Holmbeck et al., 1999; Zhou et al., 2000; Colnot et al., 2001 ). The importance of angiogenesis and vascular invasion for the growth and development of bone is also reflected in processes of bone repair and pathology, such as bone fracture healing, osteonecrosis, osteoporosis, rickets, osteoarthritis, and TD (Reeve et al., 1988; Hunter et al., 1991; Orth and Cook, 1994; Street et al., 2002; Tanaka et al., 2005; Gay et al., 2007; Lee et al., 2012b) .
Many molecules have been implicated as positive regulators of angiogenesis, including members of the VEGF family, fibroblast growth factor, transforming growth factors α and β, hepatocyte growth factor, hypoxia-inducible factor, tumor necrosis factor α, and MMP (Vu and Werb, 1998; Yancopoulos et al., 2000; Cramer et al., 2004; Carmeliet, 2005; Gay et al., 2007; Genin et al., 2012) . Among these pro-angiogenic factors, VEGF, a homodimeric protein, is regarded as the most potent angiogenic stimulator and was identified from bovine pituitary follicular cells by Ferrara and Henzel (1989) . The VEGF biology is complex because the VEGF family consists of at least 7 members [VEGF (VEGF-A-F and placenta growth factor)], and their functions are mediated by at least 3 receptors (VEG-FR-1/Flt-1, VEGFR-2/Flk-1, and VEGFR-3/Flt-4) and 2 coreceptors (neuropilin and heparan sulfate proteoglycans; Tammela et al., 2005; Dai and Rabie, 2007) . In growth plates, hypertrophic chondrocytes and chondrocytes that are not resting or proliferating express VEGF (Alini et al., 1996; Gerber et al., 1999; Bluteau et al., 2007) ; the other bone cells also express VEGF and its receptors (Deckers et al., 2000; Dai and Rabie, 2007; Corrado et al., 2013) . The role of VEGF in the pathogenesis of some disorders relating to endochondral bone formation is unclear. The fact that VEGF active proteins in vitro are unavailable has restricted further studies of the role of VEGF in these diseases, especially in avian bone disorders, although some human VEGF isoforms have been cloned and expressed, and some genetic models and special reagents have been used to explore the biological functions of VEGF (Komori et al., 1997; Zhou et al., 2000; Carmeliet, 2005; Dai and Rabie, 2007) . Artificial synthesis, tissue extraction, and expression in appropriate expression systems are often used to obtain a particular active protein in vitro. However, obtaining large amounts of some active proteins by artificial synthesis, tissue extraction, or prokaryotic expression is difficult because of high cost, complex procedures, and limited knowledge of protein characteristics. In this study, we used the eukaryotic shuttle vector pPICZα-A and Pichia strain X-33 to express chVEGF protein. The yeast vector, which contains the alcohol oxidase promoter, a α-factor secretion signal, and a Zeocin resistance gene, is commonly used for methanol-induced high-level secretion expression of recombinant proteins (Cregg et al., 2000) . Pichia strain X-33 is an ideal methylotrophic yeast host that grows with methanol as the sole source of carbon. The appropriate culture temperature, induction time, ventilation quantity, and methanol concentration depend on the target proteins and must be determined to enhance the expression of foreign proteins (Cregg et al., 2000; Li et al., 2007b) . a-e Values with the different superscripts in the same column are significantly different (P < 0.05).
1 Data are means ± SEM. Group A-D: basal diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chicken vascular endothelial growth factor (chVEGF) protein, respectively; group E-H: thiram-containing (100 mg/kg) diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chVEGF protein, respectively.
In the current study, chVEGF protein was expressed at a high level (200 mg/L) in P. pastoris after induction for 72 h at a temperature of 30°C, a methanol concentration of 5%, and shaker rate of 300 rpm. The expressed chVEGF products had molecular weights of ~46 and ~70 kDa, and were recognized by rabbit anti-chicken and goat anti-human VEGF polyclonal antibodies. Moreover, the recombinant proteins clearly stimulated angiogenesis on CAM, suggesting that they had good bioactivity. The expression of 2 products may have resulted from alternative splicing of the VEGF mRNA or protein modification after translation. These 2 proteins are the first to be reported in broilers, although many VEGF isoforms have been described in humans and other animals (Maes et al., 2004; Tammela et al., 2005; Dai and Rabie, 2007; Takimoto et al., 2009) .
Tibial dyschondroplasia, a typical disorder of endochondral ossification, is characterized by disturbed chondrocyte differentiation and deficient growth plate vascularization (Riddell, 1977; Orth and Cook, 1994; Praul et al., 2000; Farquharson, 2002) . We investigated the effects of the recombinant chVEGF proteins on BW, blood chemistry, antioxidant capacity of the liver and kidney, TD incidence, TD index, and expression of genes associated with TD in broiler chickens. The results indicate that at dosages of 10 and 30 μg/kg, the recombinant proteins had little effect on BW or TD incidence, significantly improved the antioxidant capacity of the liver and kidney in all birds, and decreased the TD index in thiram-treated birds. At a high dosage (50 μg/kg), chVEGF proteins decreased T-AOC, SOD, and GSH-Px activities in the liver and kidney of the thiram-treated birds, suggesting that the recombinant proteins promoted TD lesion recovery by enhancing the antioxidant capacity of the liver and kidney in broilers. Thiram, a dithiocarbamate, is commonly used as a TD inducer and can inhibit angiogenesis, damage liver function, and disturb cell metabolism and mineral utilization in vivo (Cereser et al., 2001; Marikovsky, 2002; Rath et al., 2005; Rasaputra et al., 2013) . Li et al. (2007a) suggested that liver dysfunction was involved in the mechanisms by which thiram induces TD. However, the role of the kidney, which is also important for the metabolism and utilization of minerals and vitamins, in TD development has not been reported previously.
Blood Ca, P, ALP, and TRAP are generally recognized as markers of bone metabolism and bone turnover. In this study, birds fed the thiram-enriched diet showed higher serum Ca and P concentrations and higher ALP activity at 21 d old than birds fed the basal diet; and thiram-treated birds injected with the recombinant chVEGF proteins showed lower serum Ca and P concentrations and TRAP activity and higher serum ALP activity compared with the controls. The chVEGF-treated birds fed the basal diet showed higher serum Ca and P concentrations and ALP and TRAP Table 3 . Serum Ca and P concentrations and alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP) activities in 21-d-old broilers (n = 10) 1 Values with different superscripts in the same column are significantly different (P < 0.05). 1 Data are means ± SEM. Group A-D: basal diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chicken vascular endothelial growth factor (chVEGF) protein, respectively; group E-H: thiram-containing (100 mg/kg) diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chVEGF protein, respectively. SOD = superoxide dismutase; GSH-Px = glutathione peroxidase; T-AOC = total antioxidant capacity.
activities than the control birds. These results suggest that the recombinant proteins altered Ca and P metabolism in vivo and that serum indexes such as ALP and TRAP activity may be inappropriate indicators of cartilage turnover in growth plates during endochondral ossification; elevated levels of ALP and TRAP were more likely to be caused by cellular metabolism in other tissues. Some reports have indicated that in TD growth plates, ALP activity is normal and TRAP activity is decreased (Lawler et al., 1988; Rath et al., 2005) .
Abnormal expression and distribution of many genes relating to endochondral ossification have been reported in avian growth plates with TD lesions (Farquharson and Jefferies, 2000; Leach and Monsonego-Ornan, 2007; Dan et al., 2009) . Type X collagen is a specific marker of differentiation of chondrocyte hypertrophy, which is expressed by prehypertrophic and hypertrophic chondrocytes in growth plates. Tibial dyschondroplasia lesions result from excessive accumulation of transitional chondrocytes that fail to undergo terminal differentiation and mineralization (Farquharson, 2002) . In TD growth plates, the synthesis of collagen X is decreased, and its distribution is mainly intracellular rather than extracellular (Bashey et al., 1989; Farquharson and Jefferies, 2000) . The expression of type X collagen mRNA in TD lesions is controversial, perhaps because of differences in sample collection time between the studies (Farquharson and Jefferies, 2000; Rath et al., 2005) . Here, we found that at 15 d old, the expression of collagen X Values with different superscripts in the same column are significantly different (P < 0.05). 1 Data are means ± SEM. Group A-D: basal diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chicken vascular endothelial growth factor (chVEGF) protein, respectively; group E-H: thiram-containing (100 mg/kg) diet group treated with 0, 10, 30, or 50 μg/kg of recombinant chVEGF protein, respectively. SOD = superoxide dismutase; GSH-Px = glutathione peroxidase; T-AOC = total antioxidant capacity. mRNA was higher in thiram-treated birds than in birds fed the basal diet, and this result is consistent with the previous report by Rath et al. (2005) ; however, at 21 d old, type X collagen gene expression in thiram-treated birds was significantly downregulated compared with its expression in birds fed the basal diet. This result suggests that collagen X synthesis and secretion were disturbed during TD lesion formation. At a dosage of 30 μg/kg, the recombinant proteins upregulated the expression of type X collagen gene in thiram-treated birds at the age of 15 d; at 21 d old, all 3 dosages of recombinant proteins upregulated type X collagen expression in thiram-treated birds, indicating that the exogenous proteins could not prevent thiram-induced TD and but could promote the recovery of chondrocyte function in growth plates with TD lesions. Some reported have indicated that the expression of Bcl-2, which is an important survival and antiapoptotic gene, is suppressed in thiram-induced TD growth plates and that chondrocytes in TD lesions are apoptotic (Praul et al., 1997; Rath et al., 2007) . We found that the expression of Bcl-2 was upregulated in thiram-treated birds at 15 d old and significantly downregulated at 21 d old, compared with its expression in basal diet-fed controls; 30 μg/kg of the recombinant proteins upregulated Bcl-2 gene expression in thiram-treated birds at 15 d old compared with the thiram-treated controls, and the exogenous proteins downregulated Bcl-2 expression at a dosage-dependent manner in thiram-treated birds at 21 d old. These results suggest that an antiapoptotic protection mechanism existed in the growth plate and that the chVEGF proteins may have promoted hypertrophic differentiation and apoptosis of chondrocytes in TD lesions by inhibiting the expression of Bcl-2 mRNA during growth plate recovery. The MMP, which are members of a family of zinc-dependent proteolytic enzymes, play a crucial role in ECM remodeling and degradation and are involved in the regulation of growth plate vascularization and chondrocyte maturation during endochondral ossification (Holmbeck et al., 1999; Inada et al., 2004; Hasky-Negev et al., 2008) . Decreased MMP activities in TD-affected growth plates have been observed, and this decreased activity may contribute to the retention of abnormal cartilage and the lack of vascularization in the proximal tibia growth plate (Rath et al., 1997; Hasky-Negev et al., 2008; Dan et al., 2009) . Matrix metalloproteinase-13, also known as collagenase-3, is expressed by cells surrounding the blood vessels and in the hypertrophic zone of the growth plates and can degrade a variety of cartilage extracellular matrix proteins including aggrecan, casein, fibronectin, and type I, III, IV, and V collagens (Armstrong et al., 2002; Wu et al., 2002; Inada et al., 2004) . Some studies have shown that gene MMP-13 expression and protein synthesis are downregulated in thiram-induced TD (Hasky-Negev et al., 2008; Dan et al., 2009; Velada et al., 2011) . However, Rath et al. (2005) found that the expression of MMP-13 mRNA is upregulated in TD-affected broilers. In the current study, we found that MMP-13 expression in thiram-treated birds was significantly downregulated in 15-d-old broilers but was recovered to the normal level in 21-d-old birds; intramuscular injection of the recombinant chVEGF proteins markedly upregulated the expression of the MMP-13 gene in thiram-treated birds in a dosage-dependent manner during TD lesion formation and growth plate recovery. These results suggest that MMP-13 plays an important role in the development of TD and that the recombinant proteins promoted abnormal ECM absorption and angiogenesis by stimulating MMP-13 expression in growth plates. Runx2, a transcription factor belonged to the Runx family, is a vital regulator of chondrocyte maturation, osteoblast differentiation, and vascular invasion (Provot and Schipani, 2005; Lee et al., 2012a) . Runx2-deficient mice exhibit delayed chondrocyte maturation, complete lack of bone formation, and disturbed vascular invasion in the developing bones (Komori et al., 1997; Inada et al., 1999; Zelzer et al., 2001) . Rath et al. (2005) suggested that thiram has no effect on Runx2 expression in thiram-treated broilers. However, the results of the current study indicate that the Runx2 expression in thiram-treated birds was significantly downregulated during the development of TD, indicating a decreased amount of hypertrophic chondrocytes; treatment with the recombinant chVEGF proteins significantly upregulated expression of Runx2 in 15-and 21-d-old thiram-treated birds compared with the expression in the controls. This result suggests that the recombinant proteins initiated the hypertrophic differentiation of arrested chondrocytes in TD by stimulating the expression of Runx2 mRNA.
In summary, we expressed the recombinant chVEGF in P. pastoris and obtained 2 bioactive chVEGF proteins. The recombinant proteins promoted the recovery of TD-affected growth plates by improving antioxidant capacity in the liver and kidney and by regulating the differential expression of genes relating to endochondral ossification at different stages of TD development; the functional deficiency of VEGF in the growth plate was involved in the etiology of TD. Further research is necessary for elucidating the differences in structure and function between the 2 protein isoforms of chVEGF and the role of the mechanisms of vascular invasion in the pathogenesis of TD.
